MRD Positivity Correlates With Allogeneic Transplant Benefits in NPM1-Mutated AML
The presence of molecular minimal residual disease following induction chemotherapy can be used to determine patients with NPM1-mutated acute myeloid leukemia who may benefit from allogeneic transplant in first remission, including those with FLT3 ITD–mutated disease.
Source: onclive.com